Evidence map›Paper›PMID 38855867›Full record

ArticleJCI insight2024

Endothelial cell sphingosine 1-phosphate receptor 1 restrains VE-cadherin cleavage and attenuates experimental inflammatory arthritis.

Nathalie Burg, Ryan Malpass, Linda Alex, Miles Tran, Eric Englebrecht, Andrew Kuo, Tania Pannelini, Margaret Minett, Kalana Athukorala, Tilla Worgall and 9 more

Abstract read
In one paragraph

Article in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Unveiling the crucial role of CD8Journal of translational autoimmunity · 2025
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Nathalie BurgHospital for Special Surgery, New York, New York, USA.
Ryan MalpassHospital for Special Surgery, New York, New York, USA.
Linda AlexHospital for Special Surgery, New York, New York, USA.
Miles TranDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Eric EnglebrechtSchool of Medicine, University of Louisville, Louisville, Kentucky, USA.
Andrew KuoVascular Biology Program, Boston Children's Hospital and Department of Surgery, Harvard Medical School, Boston, Massachusetts, USA.
Tania PanneliniHospital for Special Surgery, New York, New York, USA.
Margaret MinettHospital for Special Surgery, New York, New York, USA.
Kalana AthukoralaUniversity of Michigan School of Medicine, Ann Arbor, Michigan, USA.
Tilla WorgallDepartment of Pathology and Cell Biology, Columbia University, New York, New York, USA.
Heather J FaustDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Susan GoodmanHospital for Special Surgery, New York, New York, USA.
Bella MehtaHospital for Special Surgery, New York, New York, USA.
Michael BrennerDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Dietmar VestweberMax Planck Institute, Munster, Germany.
Kevin WeiDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Carl BlobelHospital for Special Surgery, New York, New York, USA.
Timothy HlaVascular Biology Program, Boston Children's Hospital and Department of Surgery, Harvard Medical School, Boston, Massachusetts, USA.
Jane E SalmonHospital for Special Surgery, New York, New York, USA.

Funding

Role of fibroblastic stromal cells and notch signaling in tissue inflammation in RA and SLEP01AI148102 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Michael B. Brenner · 2021 to 2026
$17.3M
PEARL: Pathway Exploration and Analysis in Renal LupusUH2AR067688 · NIAMS · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI DIAMOND, BETTY, WOFSY, DAVID · 2014 to 2020
$9.0M
Tissue Acquisition Research GroupUM2AR067678 · NIAMS · STANFORD UNIVERSITY · PI HOLERS, VERNON MICHAEL, UTZ, PAUL JOSEPH · 2014 to 2020
$8.2M
Multi-Ethnic Translational Research Optimization (METRO) Lupus ConsortiumUH2AR067689 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BUYON, JILL P, PUTTERMAN, CHAIM · 2014 to 2020
$6.3M
Mechanisms of sphingolipid signaling in vascular health and diseaseR35HL135821 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI HLA, TIMOTHY TUN · 2017 to 2023
$6.3M
Evolving Adaptive and Effector Mechanisms from Pre-RA Through Established DiseaseUH2AR067681 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI HOLERS, VERNON MICHAEL · 2014 to 2020
$5.5M
Molecular and Cellular Dissection of Early Rheumatoid ArthritisUH2AR067694 · NIAMS · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI BRENNER, MICHAEL B., GREGERSEN, PETER K. · 2014 to 2020
$5.4M
RA-SLE Molecular Deconstruction Leadership CenterUH2AR067677 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI BRENNER, MICHAEL B., RAYCHAUDHURI, SOUMYA · 2014 to 2020
$4.3M
Expanded fibroblast subset drives pathology in rheumatoid arthritisR01AR063709 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI BRENNER, MICHAEL B., RAYCHAUDHURI, SOUMYA · 2015 to 2025
$3.3M
Cellular Dynamics at the Synovium-Bone interface in RAUH2AR067690 · NIAMS · UNIVERSITY OF ROCHESTER · PI ANOLIK, JENNIFER HOWITT · 2014 to 2020
$3.0M
Myeloid sphingolipid regulation of tissue resolution and regeneration responsesR01AI173377 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Timothy Tun Hla · 2022 to 2026
$2.9M
Stanford Technology Accelerating Medicines Partnership CenterUH2AR067676 · NIAMS · STANFORD UNIVERSITY · PI ROBINSON, WILLIAM H, UTZ, PAUL JOSEPH · 2014 to 2020
$2.6M
NHLBI NIH HHS R01 HL167723NHLBI NIH HHS R35 HL135821NIAID NIH HHS P01 AI148102NIAID NIH HHS R01 AI173377NIAMS NIH HHS K08 AR077037NIAMS NIH HHS R01 AR063709NIAMS NIH HHS R01 AR073833NIAMS NIH HHS UH2 AR067676NIAMS NIH HHS UH2 AR067677NIAMS NIH HHS UH2 AR067679NIAMS NIH HHS UH2 AR067681NIAMS NIH HHS UH2 AR067685NIAMS NIH HHS UH2 AR067688NIAMS NIH HHS UH2 AR067689NIAMS NIH HHS UH2 AR067690NIAMS NIH HHS UH2 AR067691NIAMS NIH HHS UH2 AR067694NIAMS NIH HHS UM2 AR067678NIA NIH HHS R01 AG078602NIGMS NIH HHS R35 GM134907
6 · The paper itself

Abstract

In rheumatoid arthritis, inflammatory mediators extravasate from blood into joints via gaps between endothelial cells (ECs), but the contribution of ECs is not known. Sphingosine 1-phosphate receptor 1 (S1PR1), widely expressed on ECs, maintains the vascular barrier. Here, we assessed the contribution of vascular integrity and EC S1PR1 signaling to joint damage in mice exposed to serum-induced arthritis (SIA). EC-specific deletion of S1PR1 or pharmacological blockade of S1PR1 promoted vascular leak and amplified SIA, whereas overexpression of EC S1PR1 or treatment with an S1PR1 agonist delayed SIA. Blockade of EC S1PR1 induced membrane metalloproteinase-dependent cleavage of vascular endothelial cadherin (VE-cadherin), a principal adhesion molecule that maintains EC junctional integrity. We identified a disintegrin and a metalloproteinase domain 10 (ADAM10) as the principal VE-cadherin "sheddase." Mice expressing a stabilized VE-cadherin construct had decreased extravascular VE-cadherin and vascular leakage in response to S1PR1 blockade, and they were protected from SIA. Importantly, patients with active rheumatoid arthritis had decreased circulating S1P and microvascular expression of S1PR1, suggesting a dysregulated S1P/S1PR1 axis favoring vascular permeability and vulnerability. We present a model in which EC S1PR1 signaling maintains homeostatic vascular barrier function by limiting VE-cadherin shedding mediated by ADAM10 and suggest this signaling axis as a therapeutic target in inflammatory arthritis.

Indexed as

ADAM10 ProteinAntigens, CDArthritis, ExperimentalArthritis, RheumatoidCadherinsEndothelial CellsSphingosine-1-Phosphate ReceptorsAmyloid Precursor Protein SecretasesAnimalsCadherin 5Capillary PermeabilityFemaleHumansLysophospholipidsMaleMembrane ProteinsADAM10 ProteinAdam10 protein, mouseAmyloid Precursor Protein SecretasesAntigens, CDCadherin 5CadherinsLysophospholipidsMembrane ProteinsS1PR1 protein, humanS1pr1 protein, mouseSphingosineSphingosine-1-Phosphate ReceptorsArthritisEndothelial cellsInflammationVascular biology

Identifiers

PMID38855867
PMCPMC11382883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.